Don Ma is an anchor and senior business correspondent based at the network's global headquarters in New York City. Don is the anchor and producer of NTD's "Business Matters," which airs weekdays at 4:30 pm ET.

Don Ma

NTD Plus

News

Breaking news and in-depth analysis from the United States and beyond. We bring you the latest updates, exclusive insights, and sharp discussions on the most pressing issues. NTD Newsroom airs Monday–Friday from 2 p.m. to 6 p.m. ET.

NTD Newsroom

Court Rules Union Discriminated Against Flight Attendant, Awards Nearly $1 Million

Fed’s Decision to Hold Interest Rate Steady ‘Not a Surprise’: Financial Analyst

Breaking Down Arguments in Supreme Court TPS Case

‘Huge Victory for American Foreign Policy’ as UAE Set to Leave OPEC: Foreign Policy Analyst

Attempted Assassination of Trump Raises Security and Radicalization Concerns: Panelists Discuss

DHS Funding Needed ‘Right Away’ to Protect Americans: Former DHS Official

Sean Marshall is a reporter based at NTD's global headquarters in New York City, primarily covering business and technology trends. 

Sean Marshall

NYC Deed Theft Office Opened by Mayor Zohran Mamdani

The Biggest Security Breach of Shooting Was Hotel Check-In: Former Detective

Shooter Is 'Intended Product' of Communist Radicalization: Activist

‘Weaponization of Our Children’ Is Taking Place Across America: Alex Newman

NTD Newsroom Full Broadcast (April 30)

NTD Newsroom Full Broadcast (April 29)

NTD Newsroom Full Broadcast (April 28)

NTD Newsroom Full Broadcast (April 27)

NTD Newsroom Full Broadcast (April 24)

NTD Newsroom Full Broadcast (April 23)

NTD Newsroom Full Broadcast (April 22)

NTD Newsroom Full Broadcast (April 21)

NTD Newsroom Full Broadcast (April 20)

Arleen Richards is NTD's legal correspondent based at the network's global headquarters in New York City, where she covers all major legal stories. Arleen holds a Doctor of Law (J.D.).


Arleen Richards

NTD Newsroom Full Broadcast (April 17)

Naveen Athrappully is a news reporter covering business and world events at The Epoch Times.


Naveen Athrappully

Science &amp; Tech

FBI Issues Public Alert on Americans Using Foreign Apps

NTD Newsroom comprises teams of reporters, editors, and producers assigned to cover breaking news and other stories.


Fast, compelling, first-hand news from China. China in Focus airs Monday–Friday at 8 p.m. ET.

China in Focus

China Sends Warships to Pacific Drill as Tensions With Japan Rise

Reuters is a news agency owned by Thomson Reuters. It employs around 2,500 journalists and 600 photojournalists in about 200 locations worldwide writing in 16 languages.

Reuters

We present news that is truthful and based on facts, outside of the political fog. Instead of focusing on the negative things happening around us, our mission is to give our viewers a good morning with empathetic and uplifting stories. Our aim is to provide an antidote to negativity by shining a light on the best side of people. We speak to inspiring people who positively impact communities, pursue topics that represent our common human values, and will never miss an opportunity to bring you heartwarming stories.

NTD Good Morning

2 US Embassy Personnel Assigned to Cartel Case Killed in Car Accident

The Associated Press is an American not-for-profit news agency headquartered in New York City. 

The Associated Press

US News

Gunman Kills 8 Children, Including 7 of His Own, in Louisiana Mass Shooting

Flora Hua is a reporter based at NTD's global headquarters in New York City, where she covers China news, U.S.-China relations, and human rights issues. Flora primarily contributes to NTD's "China in Focus."  

Flora Hua

Trump: Seized Iranian Ship May Have ‘A Gift From China’

China News

FBI Warns Americans About Safety Risks When Traveling to China

Ryan Morgan is a reporter for The Epoch Times focusing on military and foreign affairs. He was previously a news writer for NTD. 


Ryan Morgan

Army Chief of Staff Steps Down

Wildfires Across Georgia and Florida Have Destroyed Nearly 50 Homes and Are Forcing Evacuations

News you can trust from the U.S. and around the world. Critical information and insight. We cover the stories that others don’t. NTD News Today airs Monday–Friday at 11 a.m. ET.

NTD News Today

US Issues Shelter-In-Place Order for Americans in Bahrain

Aldgra Fredly is a freelance writer covering U.S. and Asia Pacific news for The Epoch Times.

Aldgra Fredly

Secret Service Says Gunfire Reported Near White House Overnight

Lawrence Wilson covers politics for The Epoch Times.

Lawrence Wilson

Americans will have access to Zepbound and Wegovy at reduced prices starting in 2026.

The wildly popular treatments for diabetes and obesity will be available to consumers at a nearly 90 percent discount in January, under an agreement negotiated by the Trump administration with Eli Lilly and Novo Nordisk.

The drugs will also be sold to the Medicare program at reduced prices in July, enabling expanded coverage. State Medicaid programs will see savings as they opt into the agreement.

More than 16 million Americans have used Wegovy, Zepbound, or a comparable injectable weight-loss drug. Wegovy accounted for more than a quarter of all weight-loss prescriptions in 2024.

“Eli Lilly and Novo Nordisk have committed to offer Zepbound and Wegovy for Most Favored Nation prices for American patients,” President Donald Trump said in announcing the agreement on Nov. 6.

U.S. customers had been paying as much as 520 percent more than those in Europe, and up to 1,400 percent more for Wegovy.

“These are two companies that [are] behind the groundbreaking weight loss drugs that have helped millions of Americans struggling with obesity live better, longer lives,” Trump added.

For customers who buy the drugs directly from the manufacturers, the price for the starting dose of the oral formulation of the drugs will be $149, roughly 11 percent of the current list price.

For direct-pay customers, the average price for all doses, including the injectable form of the medications, will be $350, a discount of about 30 percent from current pricing.

That price will be reduced to $245 over two years, according to a senior administration official.

Medicare and Medicaid programs will pay $149 for initial oral doses, then $245 per month for all other doses. Medicare beneficiaries will make a $50 co-payment.

Under this agreement, the Medicare program will cover the drugs for weight loss under certain conditions. State Medicaid programs will have the option to do so.

Currently, 13 states cover drugs in this category, known as GLP-1 medications, for the treatment of both diabetes and weight loss. Another four states cover them only for diabetes, and 34 state Medicaid programs do not cover them.

Under the agreement, Medicare or Medicaid programs will cover Zepbound or Wegovy for weight loss only if the patient has an underlying health condition.

“We want patients to be healthier again, and we are really focused on secondary prevention,” a senior official told reporters on Nov. 6.

About 10 percent of the Medicare beneficiaries will qualify.

The expanded coverage will save the Medicare program about $300 billion by reducing the cost of medical care for obesity. Overall, obesity costs Americans more than $1 trillion annually in medical costs, according to the White House.

Medicare patients with a body mass index greater than 27 are eligible if they are diagnosed as pre-diabetic, have had a stroke, have had a stroke or myocardial infarction, or have peripheral artery disease.

Patients having a body mass index above 30 are eligible if they also have kidney disease at stage 3a or higher, heart failure with preserved ejection fraction, or uncontrolled hypertension.

Patients with a body mass index above 35 but no underlying health condition are eligible.

Future drugs released by Eli Lilly or Novo Nordisk in this category, known as GLP-1 medications, would also be available at these prices if approved for the treatment of obesity.

Drug manufacturers are required to provide lifestyle coaching on physical activity and dietary choices for those taking their medications.

Expanding Medicare coverage of these drugs for weight loss is expected to be cost-neutral, officials said, because the savings from discounts for existing diabetes patients will fund coverage for weight loss patients.

Under the terms of the agreement, Eli Lilly and Novo Nordisk also agreed to the four terms of the administration’s Most Favored Nation prescription drug pricing policy.

Those provisions are to provide all covered medications to the Medicaid program at the lowest price available in any developed nation, offer new medications to U.S. patients at the lowest available price, sell medications directly to U.S. consumers at the best available price, and use revenues realized from raising drug prices abroad to lower prices for American patients and taxpayers.

Commercial insurers will also be able to obtain lower prices, which the administration estimated will be 25 percent below the current cash price of the drugs.

<em>From <a href="https://www.theepochtimes.com/us/trump-deal-lowers-price-of-popular-weight-loss-drugs-by-nearly-90-percent-5940925">The Epoch Times</a></em>

Latest

Paywall Related

Videos

Politics

04_Top Stories

Latest Clips

Free for Subscribers

Management

03_Featured

Health News

Executive Branch

Latest and breaking news, documentaries, movies, and lifestyle content on NTD+.
 
Empower your knowledge and elevate your spirit with NTD+, your go-to destination for truthful news, insightful documentaries, and captivating lifestyle content that enriches your life.

Trump Announces Deal to Lower Prices of Popular Weight-Loss Drugs by Nearly 90 Percent

Full Episodes